Stockscreener 앱 받기
110.22
8.05%
8.21
시간 외 거래:
108.00
-2.22
-2.01%
전일 마감가:
$102.01
열려 있는:
$103.56
하루 거래량:
848.51K
Relative Volume:
1.17
시가총액:
$5.10B
수익:
-
순이익/손실:
$-162.72M
주가수익비율:
-30.02
EPS:
-3.6714
순현금흐름:
$-144.89M
1주 성능:
-2.04%
1개월 성능:
+2.64%
6개월 성능:
+112.21%
1년 성능:
+948.72%
1일 변동 폭
$103.56
$110.61
1주일 범위
$100.01
$115.08
52주 변동 폭
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
명칭
Celcuity Inc
전화
763-392-0767
주소
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
110.22 | 4.72B | 0 | -162.72M | -144.89M | -3.6714 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Stifel | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-02-22 | 개시 | Stifel | Buy |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-08 | 개시 | Canaccord Genuity | Buy |
| 2021-09-07 | 개시 | Jefferies | Buy |
| 2021-07-29 | 개시 | Cowen | Outperform |
| 2021-07-27 | 개시 | Needham | Buy |
| 2021-01-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-11 | 재개 | Craig Hallum | Buy |
| 2018-11-20 | 개시 | H.C. Wainwright | Buy |
모두보기
Celcuity Inc 주식(CELC)의 최신 뉴스
Celcuity Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Transcript : Celcuity Inc., Q4 2025 Earnings Call, Mar 25, 2026 - marketscreener.com
Celcuity Q4 Earnings Call Highlights - Yahoo Finance
CELC: FDA priority review, strong trial data, and robust cash position set stage for 2026 launch - TradingView
Earnings call transcript: Celcuity beats Q4 2025 EPS forecast, stock rises - Investing.com
Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib - ChartMill
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.33 EPS - MarketBeat
CELCUITY ($CELC) Releases Q4 2025 Earnings - Quiver Quantitative
Celcuity Q4 Adjusted Loss Narrows - marketscreener.com
Celcuity Inc. reports release of fourth quarter and full year 2025 financial results and provides corporate update - marketscreener.com
Celcuity Inc. Reports Release Of Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update - TradingView
BRIEF-Celcuity Q4 Adjusted EPS USD -0.73 Vs. IBES Estimate USD -1.04 - TradingView
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Celcuity earnings up next as breast cancer drug nears approval By Investing.com - Investing.com Canada
Why Celcuity’s Hot Stock Is Suddenly Cooling - TipRanks
Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result - MSN
Aug Drivers: Is Celcuity Inc stock a smart retirement pick2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Celcuity (CELC) Projected to Post Earnings on Monday - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
Celcuity Inc.: Fundamental Analysis and Financial Ratings | 7VR | US15102K1007 - marketscreener.com
CELC Stock Price, Quote & Chart | CELCUITY INC (NASDAQ:CELC) - ChartMill
Aug Breakouts: Should I set a stop loss on Celcuity Inc2026 Sentiment & Risk Controlled Daily Plans - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating - Sahm
Celcuity (CELC) price target increased by 11.17% to 108.57 - MSN
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call - The Manila Times
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and ... - Bluefield Daily Telegraph
Why (CELC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Needham & Company LLC Reiterates Buy Rating for Celcuity (NASDAQ:CELC) - MarketBeat
HighVista Strategies LLC Purchases New Position in Celcuity, Inc. $CELC - MarketBeat
49,281 Shares in Celcuity, Inc. $CELC Purchased by Granahan Investment Management LLC - MarketBeat
Celcuity publishes Phase 3 trial results in medical journal - Investing.com Nigeria
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Celcuity prices $248.7M debt, stock offerings - MSN
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders - Yahoo Finance
90,000 Shares in Celcuity, Inc. $CELC Purchased by Boxer Capital Management LLC - MarketBeat
Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC - MarketBeat
The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data - simplywall.st
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - The Motley Fool
Celcuity: Undervalued Pipeline with Differentiated Clinical Profile Supports Buy Rating - TipRanks
15,000 Shares in Celcuity, Inc. $CELC Purchased by Aristides Capital LLC - MarketBeat
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026 - Meyka
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review - simplywall.st
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook - Investing.com South Africa
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis
Buyback Watch: Can Celcuity Inc ride the EV waveEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount? - simplywall.st
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts - Sahm
CELC: Gedatolisib demonstrates leading efficacy in breast cancer, with launch and global expansion underway - TradingView
CELC: Gedatolisib delivers record efficacy in breast cancer, with launch and global expansion plans advancing - TradingView
Celcuity Inc (CELC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):